ArticleCancer medicine2014
Testicular self-examination and testicular cancer: a cost-utility analysis.
Article in Cancer medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 43 citations in OpenAlex.
- Promoting men's awareness, self-examination, and help-seeking for testicular disorders: a systematic review of interventions.HRB open research · 2018Pooled it
- Whole-proteome phage immunoprecipitation sequencing reveals germ cell tumor-specific immunosignature.Nature communications · 2026Article
- Testicular Cancer: Diagnosis, Treatment, and Biomarker Advances.Research and reports in urology · 2026Review
- Article
- Discriminating Malignant from Benign Testicular Masses Using Multiparametric Magnetic Resonance Imaging-A Prospective Single-Center Study.Journal of clinical medicine · 2024Article
- Sonoelastography for Testicular Tumor Identification: A Systematic Review and Meta-Analysis of Diagnostic Test Accuracy.Cancers · 2023Review
- Testicular self-examination for early detection of testicular cancer.World journal of urology · 2023Review
- Leveraging Systematic Reviews to Explore Disease Burden and Costs of Per- and Polyfluoroalkyl Substance Exposures in the United States.Exposure and health · 2023Article
- Testicular Cancer Knowledge and Viewpoints of American Men.Urology practice · 2022Article
- Screening for cancers with a good prognosis: The case of testicular germ cell cancer.Cancer medicine · 2021Article
- Development of a 3D-printed testicular cancer model for testicular examination education.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2021Article
- Article
- Recommendations for Treating Males: An Ethical Rationale for the Inclusion of Testicular Self-Examination (TSE) in a Standard of Care.American journal of men's health · 2018Article
- "Off-Label" Usage of Testicular Self-Examination (TSE): Benefits Beyond Cancer Detection.American journal of men's health · 2018Article
- Performing Testicular Self-Examination, Driving Automobiles, and Anxiety: What Is the Logical Link?American journal of men's health · 2018Article
- Eclipsed by the Prostate: Expanding Testicular Cancer Scholarship Through Years of Potential Life Lost and Economic Productivity.American journal of men's health · 2017Article
- Testicular Cancer Awareness and Knowledge: Is It the Same? Exploratory Study in a Mixed-Gender Population.Journal of cancer education : the official journal of the American Association for Cancer Education · 2017Article
- From 'D' to 'I': A critique of the current United States preventive services task force recommendation for testicular cancer screening.Preventive medicine reports · 2016Review
- Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The United States Preventive Services Task Force (USPSTF) has recommended against testicular self-examinations (TSE) or clinical examination for testicular cancer screening. However, in this recommendation there was no consideration of the significant fiscal cost of treating advanced disease versus evaluation of benign disease. In this study, a cost-utility validation for TSE was performed. The cost of treatment for an advanced-stage testicular tumor (both seminomatous and nonseminomatous) was compared to the cost of six other scenarios involving the clinical assessment of a testicular mass felt during self-examination (four benign and two early-stage malignant). Medicare reimbursements were used as an estimate for a national cost standard. The total treatment cost for an advanced-stage seminoma ($48,877) or nonseminoma ($51,592) equaled the cost of 313-330 benign office visits ($156); 180-190 office visits with scrotal ultrasound ($272); 79-83 office visits with serial scrotal ultrasounds and labs ($621); 6-7 office visits resulting in radical inguinal orchiectomy for benign pathology ($7,686) or 2-3 office visits resulting in treatment and surveillance of an early-stage testicular cancer ($17,283: seminoma, $26,190: nonseminoma). A large number of clinical evaluations based on the TSE for benign disease can be made compared to the cost of one missed advanced-stage tumor. An average of 2.4 to 1 cost benefit ratio was demonstrated for early detected testicular cancer versus advanced-stage disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.